294 related articles for article (PubMed ID: 37267435)
1. Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.
Schulz E; Aplan PD; Freeman SD; Pavletic SZ
Blood Adv; 2023 Aug; 7(16):4381-4394. PubMed ID: 37267435
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
Shapiro RM; Kim DDH
Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
[TBL] [Abstract][Full Text] [Related]
3. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
4. Applications of Circulating Tumor DNA in Myelodysplastic Syndromes and Acute Myeloid Leukemia: Promises and Challenges.
Xue Y; Xia X; Liu X; Zheng Y; Gu H; Wang X
Front Biosci (Landmark Ed); 2024 Feb; 29(2):86. PubMed ID: 38420833
[TBL] [Abstract][Full Text] [Related]
5. Current status and trends in the diagnostics of AML and MDS.
Shumilov E; Flach J; Kohlmann A; Banz Y; Bonadies N; Fiedler M; Pabst T; Bacher U
Blood Rev; 2018 Nov; 32(6):508-519. PubMed ID: 29728319
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS.
Rautenberg C; Lauseker M; Kaivers J; Jäger P; Fischermanns C; Pechtel S; Haas R; Kobbe G; Germing U; Schroeder T
Eur J Haematol; 2021 Aug; 107(2):283-292. PubMed ID: 33987857
[TBL] [Abstract][Full Text] [Related]
7. When to use which molecular prognostic scoring system in the management of patients with MDS?
Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
[TBL] [Abstract][Full Text] [Related]
8. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
Kohlmann A; Bacher U; Schnittger S; Haferlach T
Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
[TBL] [Abstract][Full Text] [Related]
9. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
10. Does mutational burden add to other prognostic factors in MDS?
Nazha A
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101098. PubMed ID: 31779975
[TBL] [Abstract][Full Text] [Related]
11. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
Hughes CFM; Gallipoli P; Agarwal R
Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
[TBL] [Abstract][Full Text] [Related]
12. The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
DeZern AE; Greenberg PL
Blood; 2023 Dec; 142(26):2258-2267. PubMed ID: 37562001
[TBL] [Abstract][Full Text] [Related]
13. Getting personal with myelodysplastic syndromes: is now the right time?
Chokr N; Pine AB; Bewersdorf JP; Shallis RM; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Apr; 12(4):215-224. PubMed ID: 30977414
[TBL] [Abstract][Full Text] [Related]
14. Risk stratifying MDS in the time of precision medicine.
Cazzola M
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):375-381. PubMed ID: 36485160
[TBL] [Abstract][Full Text] [Related]
15. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes.
Kobbe G; Schroeder T; Rautenberg C; Kaivers J; Gattermann N; Haas R; Germing U
Expert Rev Hematol; 2019 Oct; 12(10):821-831. PubMed ID: 31322458
[No Abstract] [Full Text] [Related]
17. Clinical utility and real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes.
Banaszak LG; Reinig E; Lasarev MR; Mattison RJ
Leuk Lymphoma; 2022 Mar; 63(3):684-693. PubMed ID: 34865601
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes].
Yokoyama K
Rinsho Ketsueki; 2021; 62(5):486-495. PubMed ID: 34248126
[TBL] [Abstract][Full Text] [Related]
19. Precision Medicine in Myeloid Malignancies: Hype or Hope?
Upadhyay Banskota S; Khanal N; Marar RI; Dhakal P; Bhatt VR
Curr Hematol Malig Rep; 2022 Dec; 17(6):217-227. PubMed ID: 35972641
[TBL] [Abstract][Full Text] [Related]
20. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
